Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Chen, Xufeng ^a,b   Radany, Eric H ^a   Wong, Patty ^a   Ma, Shenglin ^b   Wu, Kan ^b   Wang, Bing ^b   Wong, Jeffrey Y C ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; RAD51 PROTEIN; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA END JOINING REPAIR; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RADIOSENSITIVITY; RADIOSENSITIZATION;

CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTEIN KINASE C; RAD51 RECOMBINASE; RADIATION TOLERANCE;

EID: 84893193291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084515     Document Type: Article

References (56)

1. Dusenbery KE, Daniels KA, McClure JS, McGlave PB, Ramsay NK et al. (1995) Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 31: 119-128. doi:10.1016/0360-3016(94)00335-I. PubMed: 7995742.
2. Blaise D, Maraninchi D, Michallet M, Reiffers J, Jouet JP et al. (2001) Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 97: 3669-3671. doi:10.1182/blood. V97.11.3669. PubMed: 11392326.
3. Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S et al. (2009) Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 73: 273-279. doi:10.1016/j.ijrobp. 2008.04.071. PubMed: 18786784.
4. Wong JY, Forman S, Somlo G, Rosenthal J, Liu A et al. (2013) Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 85: 148-156. doi:10.1016/j.ijrobp. 2012.03.033. PubMed: 22592050.
5. Ward JF (1994) The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol 66: 427-432. doi:10.1080/09553009414551401. PubMed: 7983426.
6. Dikomey E, Brammer I, Johansen J, Bentzen SM, Overgaard J (2000) Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients. Int J Radiat Oncol Biol Phys 46: 481-490. doi:10.1016/S0360-3016(99)00335-1. PubMed: 10661357.
7. Mukherjee B, Choy H, Nirodi C, Burma S (2010) Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. Semin Radiat Oncol 20: 250-257
8. Sak A, Stueben G, Groneberg M, Böcker W, Stuschke M (2005) Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer 92: 1089-1097. doi:10.1038/sj.bjc.6602457. PubMed: 15785736.
9. Kuroda S, Urata Y, Fujiwara T (2012) Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization. Acta Med Okayama 66: 83-92. PubMed: 22525466.
10. Chen X, Wong P, Radany EH, Stark JM, Laulier C et al. (2012) Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res 10: 1052-1064. doi:10.1158/1541-7786.MCR-11-0587. PubMed: 22729783.
11. Baumann P, West SC (1998) Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23: 247-251. doi:10.1016/S0968-0004(98)01232-8. PubMed: 9697414.
12. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S et al. (2002) Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62: 219-225. PubMed: 11782381.
13. Hine CM, Seluanov A, Gorbunova V (2012) Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Mol Ther 20: 347-355. doi:10.1038/mt.2011.215. PubMed: 22008909.
14. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH et al. (2001) Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 29: 1534-1538. doi:10.1093/nar/29.7.1534. PubMed: 11266555.
15. Gunn A, Bennardo N, Cheng A, Stark JM (2011) Correct end use during end joining of multiple chromosomal double strand breaks is influenced by repair protein RAD50, DNA-dependent protein kinase DNA-PKcs, and transcription context. J Biol Chem 286: 42470-42482. doi:10.1074/jbc.M111.309252. PubMed: 22027841.
16. Fan J, Li L, Small D, Rassool F (2010) Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood 116: 5298-5305. doi:10.1182/blood-2010-03-272591. PubMed: 20807885.
17. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, Gorbunova V (2004) DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci U S A 101: 7624-7629. doi:10.1073/pnas. 0400726101. PubMed: 15123826.
18. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. doi:10.1016/0065-2571(84)90007-4. PubMed: 6382953.
19. Needham LA, Davidson AH, Bawden LJ, Belfield A, Bone EA et al. (2011) Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J Pharmacol Exp Ther 339: 132-142. doi:10.1124/jpet.111.183640. PubMed: 21778281.
20. Banáth JP, Klokov D, MacPhail SH, Banuelos CA, Olive PL (2010) Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer 10: 4. doi:10.1186/1471-2407-10-4. PubMed: 20051134.
21. Taneja N, Davis M, Choy JS, Beckett MA, Singh R et al. (2004) Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 279: 2273-2280. doi:10.1074/jbc.M310030200. PubMed: 14561744.
22. Sallmyr A, Fan J, Rassool FV (2008) Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 270: 1-9. doi:10.1016/j.canlet.2008. 03.036. PubMed: 18467025.
23. Li Y, Shimizu H, Xiang SL, Maru Y, Takao N et al. (2002) Arg tyrosine kinase is involved in homologous recombinational. DNA Repair - Biochem Biophys Res Commun 299: 697-702. doi:10.1016/S0006-291X(02)02692-X.
24. Shimizu H, Popova M, Fleury F, Kobayashi M, Hayashi N et al. (2009) c-ABL tyrosine kinase stabilizes RAD51 chromatin association. Biochem Biophys Res Commun 382: 286-291. doi:10.1016/j.bbrc.2009.03.020. PubMed: 19285032.
25. Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3: 650-665. doi:10.1038/nrc1169. PubMed: 12951584.
26. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439. doi:10.1182/blood.V97.8.2434. PubMed: 11290608.
27. Sheikhha MH, Awan A, Tobal K, Liu Yin JA (2003) Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J 4: 41-46. doi:10.1038/sj.thj.6200224. PubMed: 12692519.
28. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D et al. (2008) Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111: 3173-3182. doi:10.1182/blood-2007-05-092510. PubMed: 18192505.
29. Li L, Zhang L, Fan J, Greenberg K, Desiderio S et al. (2011) Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice. Blood 117: 3131-3139. doi:10.1182/blood-2010-05-286070. PubMed: 21228325.
30. Sallmyr A, Tomkinson AE, Rassool FV (2008) Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 112: 1413-1423. doi:10.1182/blood-2007-07-104257. PubMed: 18524993.
31. Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M et al. (2006) DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 20: 2130-2136. doi:10.1038/sj.leu.2404439. PubMed: 17066094.
32. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681. doi:10.1124/pr.58.3.10. PubMed: 16968952.
33. Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H et al. (1989) Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 7: 45-49. PubMed: 2642539.
34. Shulman LN, Tarbell NJ, Storen E, Marcus K, Mauch PM (1998) Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission. Int J Radiat Oncol Biol Phys 42: 1113-1117. doi:10.1016/S0360-3016(98)00344-7. PubMed: 9869237.
35. Appelbaum FR (2009) Optimising the conditioning regimen for acute myeloid leukaemia. Best Pract Res Clin Haematol 22: 543-550. doi:10.1016/j.beha.2009. 10.004. PubMed: 19959106.
36. Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS et al. (2008) Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 14: 282-289. doi:10.1016/j.bbmt.2007.12.488. PubMed: 18275894.
37. Wong JY, Liu A, Schultheiss T, Popplewell L, Stein A et al. (2006) Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant 12: 306-315. doi:10.1016/j.bbmt.2005.10.026. PubMed: 16503500.
38. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI et al. (1991) Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77: 1660-1665. PubMed: 2015394.
39. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31. doi:10.1016/j.jmb.2004.02.006. PubMed: 15050820.
40. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468. doi:10.1200/JCO.2009.22.1291. PubMed: 19826124.
41. Martínez-Iglesias O, Ruiz-Llorente L, Sánchez- Martínez R, García L, Zambrano A et al. (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10: 395-398. doi:10.1007/s12094-008-0221-x. PubMed: 18628067.
42. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F et al. (2012) Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 30: 2204-2210. doi:10.1200/JCO.2011.38.3265. PubMed: 22585696.
43. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C et al. (2010) A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 150: 72-82. PubMed: 20456355.
44. Petruccelli LA, Dupéré-Richer D, Pettersson F, Retrouvey H, Skoulikas S et al. (2011) Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLOS ONE 6: e20987. doi:10.1371/journal. pone.0020987. PubMed: 21695163.
45. Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A et al. (2012) Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle 11: 3219-3226. doi:10.4161/cc.21565. PubMed: 22895185.
46. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A 107: 14639-14644. doi:10.1073/pnas.1008522107. PubMed: 20679231.
47. Subramanian C, Opipari AW Jr., Bian X, Castle VP, Kwok RP (2005) Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 4842-4847. doi:10.1073/pnas. 0408351102. PubMed: 15778293.
48. Doepfner KT, Boller D, Arcaro A (2007) Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 63: 215-230. doi:10.1016/j.critrevonc.2007.05.005. PubMed: 17658267.
49. Advani AS (2005) FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications. Curr Pharm Des 11: 3449-3457. doi:10.2174/138161205774370807. PubMed: 16250847.
50. Govedarovic N, Marjanovic G (2011) Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia. J BUON 16: 108-111. PubMed: 21674859.
51. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B et al. (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65: 9643-9650. doi:10.1158/0008-5472.CAN-05-0422. PubMed: 16266983.
52. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G et al. (2012) Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective. Analysis - J Clin Oncol.
53. Gilliland DG, Griffin JD (2002) Role of FLT3 in leukemia. Curr Opin Hematol 9: 274-281. doi:10.1097/00062752-200207000-00003. PubMed: 12042700.
54. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S et al. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108: 3262-3270. doi:10.1182/blood-2006-04-015560. PubMed: 16857985.
55. Weisberg E, Barrett R, Liu Q, Stone R, Gray N et al. (2009) FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 12: 81-89. doi:10.1016/j.drup.2009.04.001. PubMed: 19467916.
56. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54-60. doi:10.1182/blood-2004-03-0891. PubMed: 15345597.